Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 136

    1.

    Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).

    Pillai SK, Wong JK, Barbour JD.

    Retrovirology. 2008 Mar 13;5:26.

    PMID:
    18339206
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.

    He Z, Zhang W, Chen G, Xu R, Yu XF.

    J Mol Biol. 2008 Sep 12;381(4):1000-11. Epub 2008 Jun 28.

    PMID:
    18619467
    [PubMed - indexed for MEDLINE]
    3.

    Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.

    Dang Y, Wang X, York IA, Zheng YH.

    J Virol. 2010 Sep;84(17):8561-70. Epub 2010 Jun 30.

    PMID:
    20592083
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.

    Izumi T, Shirakawa K, Takaori-Kondo A.

    Mini Rev Med Chem. 2008 Mar;8(3):231-8. Review.

    PMID:
    18336343
    [PubMed - indexed for MEDLINE]
    5.

    HIV-1 Vif, APOBEC, and intrinsic immunity.

    Goila-Gaur R, Strebel K.

    Retrovirology. 2008 Jun 24;5:51. Review.

    PMID:
    18577210
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.

    Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF.

    PLoS One. 2008;3(12):e3963. Epub 2008 Dec 17.

    PMID:
    19088851
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.

    Russell RA, Pathak VK.

    J Virol. 2007 Aug;81(15):8201-10. Epub 2007 May 23.

    PMID:
    17522216
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.

    Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK.

    J Virol. 2009 Feb;83(4):1992-2003. Epub 2008 Nov 26.

    PMID:
    19036809
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].

    Fan B, Cen S, Jiang JD.

    Yao Xue Xue Bao. 2008 Jul;43(7):678-82. Review. Chinese.

    PMID:
    18819469
    [PubMed - indexed for MEDLINE]
    10.

    APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.

    Han Y, Wang X, Dang Y, Zheng YH.

    PLoS Pathog. 2008 Jul 4;4(7):e1000095.

    PMID:
    18604271
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.

    Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK.

    Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5652-7. Epub 2004 Mar 30.

    PMID:
    15054139
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.

    Fourati S, Malet I, Binka M, Boukobza S, Wirden M, Sayon S, Simon A, Katlama C, Simon V, Calvez V, Marcelin AG.

    AIDS. 2010 Sep 24;24(15):2313-21.

    PMID:
    20729708
    [PubMed - indexed for MEDLINE]
    13.

    Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.

    Yamashita T, Nomaguchi M, Miyake A, Uchiyama T, Adachi A.

    Microbes Infect. 2010 Feb;12(2):166-71. Epub 2009 Nov 26.

    PMID:
    19944180
    [PubMed - indexed for MEDLINE]
    14.

    APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

    Sadler HA, Stenglein MD, Harris RS, Mansky LM.

    J Virol. 2010 Jul;84(14):7396-404. Epub 2010 May 12.

    PMID:
    20463080
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

    Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R.

    Microbiol Mol Biol Rev. 2009 Jun;73(2):211-32. Review.

    PMID:
    19487726
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism.

    Marin M, Golem S, Rose KM, Kozak SL, Kabat D.

    J Virol. 2008 Jan;82(2):987-98. Epub 2007 Oct 31.

    PMID:
    17977970
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    17.

    A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.

    Chen G, He Z, Wang T, Xu R, Yu XF.

    J Virol. 2009 Sep;83(17):8674-82. Epub 2009 Jun 17.

    PMID:
    19535450
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    18.

    Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.

    Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM.

    J Virol. 2004 Jun;78(11):6073-6.

    PMID:
    15141007
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    19.

    Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.

    Iwabu Y, Kinomoto M, Tatsumi M, Fujita H, Shimura M, Tanaka Y, Ishizaka Y, Nolan D, Mallal S, Sata T, Tokunaga K.

    J Biol Chem. 2010 Nov 12;285(46):35350-8. Epub 2010 Sep 10.

    PMID:
    20833716
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

    Dang Y, Davis RW, York IA, Zheng YH.

    J Virol. 2010 Jun;84(11):5741-50. Epub 2010 Mar 24.

    PMID:
    20335268
    [PubMed - indexed for MEDLINE]
    Free PMC Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk